{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T00:45:11Z","timestamp":1794530711390,"version":"4.9.1"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T00:00:00Z","timestamp":1692748800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["202102010287"],"award-info":[{"award-number":["202102010287"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018568","name":"Special Fund Project for Science and Technology Innovation Strategy of Guangdong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018568","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021A1515012573"],"award-info":[{"award-number":["2021A1515012573"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2022A1515010395"],"award-info":[{"award-number":["2022A1515010395"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81803919"],"award-info":[{"award-number":["81803919"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82104495"],"award-info":[{"award-number":["82104495"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82174161"],"award-info":[{"award-number":["82174161"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.biopha.2023.115373","type":"journal-article","created":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T04:47:39Z","timestamp":1693198059000},"page":"115373","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions"],"prefix":"10.1016","volume":"166","author":[{"given":"Chunping","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sien","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaojing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiding","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longmei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zebo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiyuan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxiong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wensheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip C.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2023.115373_bib1","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s11864-019-0646-1","article-title":"Cardiotoxicity of contemporary breast cancer treatments","volume":"20","author":"Lee Chuy","year":"2019","journal-title":"Curr. Treat. Options Oncol."},{"issue":"47","key":"10.1016\/j.biopha.2023.115373_bib2","first-page":"6","article-title":"Cardiotoxicity of cancer chemotherapy in clinical practice","volume":"2019","author":"Jain","year":"1995","journal-title":"Hosp. Pr."},{"key":"10.1016\/j.biopha.2023.115373_bib3","first-page":"524","article-title":"Breast cancer statistics, 2022","volume":"72","author":"Giaquinto","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biopha.2023.115373_bib4","doi-asserted-by":"crossref","first-page":"3889","DOI":"10.1093\/eurheartj\/ehz766","article-title":"A population-based study of cardiovascular disease mortality risk in US cancer patients","volume":"40","author":"Sturgeon","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2023.115373_bib5","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.breast.2022.06.007","article-title":"Anthracyclines in the treatment of early breast cancer friend or foe?","volume":"65","author":"Vuger","year":"2022","journal-title":"Breast"},{"key":"10.1016\/j.biopha.2023.115373_bib6","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2023.115373_bib7","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fphys.2018.00167","article-title":"Antineoplastic drug-induced cardiotoxicity: a redox perspective","volume":"9","author":"Varricchi","year":"2018","journal-title":"Front Physiol."},{"key":"10.1016\/j.biopha.2023.115373_bib8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s10549-019-05303-y","article-title":"HER2+ breast cancer treatment and cardiotoxicity: monitoring and management","volume":"177","author":"Jerusalem","year":"2019","journal-title":"Breast Cancer Res Treat."},{"key":"10.1016\/j.biopha.2023.115373_bib9","first-page":"131","article-title":"Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms","author":"Moslehi","year":"2021","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.biopha.2023.115373_bib10","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/HCO.0000000000000619","article-title":"Risk factors for chemotherapy-related cardiac toxicity","volume":"34","author":"Polonsky","year":"2019","journal-title":"Curr. Opin. Cardiol."},{"key":"10.1016\/j.biopha.2023.115373_bib11","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines: the task force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2023.115373_bib12","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American society of clinical oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2023.115373_bib13","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.mayocp.2014.05.013","article-title":"Evaluation and management of patients with heart disease and cancer: cardio-oncology","volume":"89","author":"Herrmann","year":"2014","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.biopha.2023.115373_bib14","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur. J. Heart Fail"},{"key":"10.1016\/j.biopha.2023.115373_bib15","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/ejhf.1957","volume":"22","author":"Celutkiene","year":"2020","journal-title":"Eur. J. Heart Fail"},{"key":"10.1016\/j.biopha.2023.115373_bib16","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCIMAGING.112.973321","article-title":"Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab","volume":"5","author":"Sawaya","year":"2012","journal-title":"Circ. Cardiovasc Imaging"},{"key":"10.1016\/j.biopha.2023.115373_bib17","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1016\/j.jacc.2014.01.073","article-title":"Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: a systematic review","volume":"63","author":"Thavendiranathan","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.biopha.2023.115373_bib18","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/jmri.26895","article-title":"MRI in cardio-oncology: a review of cardiac complications in oncologic care","volume":"50","author":"Jeong","year":"2019","journal-title":"J. Magn. Reson Imaging"},{"key":"10.1016\/j.biopha.2023.115373_bib19","doi-asserted-by":"crossref","first-page":"3429","DOI":"10.1200\/JCO.2009.26.7294","article-title":"Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging","volume":"28","author":"Walker","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2023.115373_bib20","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1249\/MSS.0000000000001970","article-title":"Persistent Impairment in Cardiopulmonary Fitness after Breast Cancer Chemotherapy","volume":"51","author":"Foulkes","year":"2019","journal-title":"Med Sci. Sports Exerc"},{"key":"10.1016\/j.biopha.2023.115373_bib21","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/2047487318811181","article-title":"Exercise as a diagnostic and therapeutic tool for the prevention of cardiovascular dysfunction in breast cancer patients","volume":"26","author":"Howden","year":"2019","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.biopha.2023.115373_bib22","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1002\/ehf2.13365","article-title":"Adjuvant breast cancer treatments cardiotoxicity and modern methods of detection and prevention of cardiac complications","volume":"8","author":"Bikiewicz","year":"2021","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.biopha.2023.115373_bib23","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3389\/fonc.2014.00277","article-title":"Serum biomarkers for the detection of cardiac toxicity after chemotherapy and radiation therapy in breast cancer patients","volume":"4","author":"Tian","year":"2014","journal-title":"Front Oncol."},{"key":"10.1016\/j.biopha.2023.115373_bib24","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.jcmg.2012.11.017","article-title":"Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease","volume":"6","author":"Drafts","year":"2013","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.biopha.2023.115373_bib25","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1139\/cjpp-2012-0398","article-title":"Early detection of anthracycline-mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twist","volume":"91","author":"Mornos","year":"2013","journal-title":"Can. J. Physiol. Pharm."},{"key":"10.1016\/j.biopha.2023.115373_bib26","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.15537\/1658-3175.3067","article-title":"Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy","volume":"26","author":"Soker","year":"2005","journal-title":"Saudi Med J."},{"key":"10.1016\/j.biopha.2023.115373_bib27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0096736","article-title":"BNP predicts chemotherapy-related cardiotoxicity and death: comparison with gated equilibrium radionuclide ventriculography","volume":"9","author":"Skovgaard","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2023.115373_bib28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2023.115373_bib29","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/jat.4309","article-title":"MicroRNA-34a-5p as a promising early circulating preclinical biomarker of doxorubicin-induced chronic cardiotoxicity","volume":"42","author":"Desai","year":"2022","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.biopha.2023.115373_bib30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10741-017-9653-0","article-title":"Role of microRNAs in doxorubicin-induced cardiotoxicity: an overview of preclinical models and cancer patients","volume":"23","author":"Ruggeri","year":"2018","journal-title":"Heart Fail Rev."},{"key":"10.1016\/j.biopha.2023.115373_bib31","article-title":"Soluble urokinase plasminogen activator receptor is associated with subclinical myocardial impairment by speckle tracking echocardiography in lung cancer patients","volume":"8","author":"Manshad","year":"2021","journal-title":"Front Cardiovasc Med."},{"key":"10.1016\/j.biopha.2023.115373_bib32","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.31557\/APJCP.2021.22.10.3355","article-title":"Serum biomarkers for chemotherapy cardiotoxicity risk detection of breast cancer patients","volume":"22","author":"Hasan","year":"2021","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.biopha.2023.115373_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s11897-019-00450-1","article-title":"Reappraisal of inflammatory biomarkers in heart failure","volume":"17","author":"Chaikijurajai","year":"2020","journal-title":"Curr. Heart Fail Rep."},{"key":"10.1016\/j.biopha.2023.115373_bib34","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s11886-017-0846-x","article-title":"Cardiac complications of cancer therapy: pathophysiology, identification, prevention, treatment, and future directions","volume":"19","author":"Jain","year":"2017","journal-title":"Curr. Cardiol. Rep."},{"key":"10.1016\/j.biopha.2023.115373_bib35","doi-asserted-by":"crossref","first-page":"228","DOI":"10.5603\/CJ.a2020.0062","article-title":"Incidence of long-term cardiotoxicity and evolution of the systolic function in patients with breast cancer treated with anthracyclines","volume":"29","author":"Mata Caballero","year":"2022","journal-title":"Cardiol. J."},{"key":"10.1016\/j.biopha.2023.115373_bib36","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/0284186X.2022.2082884","article-title":"Real-life incidence of cardiotoxicity and associated risk factors in sarcoma patients receiving doxorubicin","volume":"61","author":"Vitfell-Rasmussen","year":"2022","journal-title":"Acta Oncol."},{"key":"10.1016\/j.biopha.2023.115373_bib37","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40259-016-0162-9","article-title":"Trastuzumab in the treatment of breast cancer","volume":"30","author":"Maximiano","year":"2016","journal-title":"BioDrugs"},{"key":"10.1016\/j.biopha.2023.115373_bib38","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.cjco.2021.06.019","article-title":"Pertuzumab cardiotoxicity in patients with HER2-positive cancer: a systematic review and meta-analysis","volume":"3","author":"Alhussein","year":"2021","journal-title":"CJC Open"},{"key":"10.1016\/j.biopha.2023.115373_bib39","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1158\/1535-7163.MCT-15-0741","article-title":"Trastuzumab, but Not Pertuzumab, Dysregulates HER2 Signaling to Mediate Inhibition of Autophagy and Increase in Reactive Oxygen Species Production in Human Cardiomyocytes","volume":"15","author":"Mohan","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.biopha.2023.115373_bib40","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/ajh.26642","article-title":"Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring","volume":"97","author":"Jabbour","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.biopha.2023.115373_bib41","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s10147-007-0699-1","article-title":"The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias","volume":"12","author":"Maekawa","year":"2007","journal-title":"Int J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2023.115373_bib42","first-page":"79","article-title":"Cardiovascular toxicity associated with tyrosine kinase inhibitor therapy in chronic myeloid leukemia","volume":"1","author":"Binzaid","year":"2021","journal-title":"Gulf J. Oncol."},{"key":"10.1016\/j.biopha.2023.115373_bib43","first-page":"1024","article-title":"[Tyrosine kinase inhibitor-associated cardiovascular adverse events in chronic myeloid leukemia]","volume":"62","author":"Miyazaki","year":"2021","journal-title":"Rinsho Ketsueki"},{"key":"10.1016\/j.biopha.2023.115373_bib44","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1002\/ijc.33119","article-title":"Risk of QTc prolongation among cancer patients treated with tyrosine kinase inhibitors","volume":"147","author":"Abu Rmilah","year":"2020","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.biopha.2023.115373_bib45","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s12012-020-09565-7","article-title":"Mechanisms of the cardiac myocyte-damaging effects of dasatinib","volume":"20","author":"Hasinoff","year":"2020","journal-title":"Cardiovasc Toxicol."},{"key":"10.1016\/j.biopha.2023.115373_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin(R)) in cancer treatment: a review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.biopha.2023.115373_bib47","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s40261-014-0222-1","article-title":"Bevacizumab increases the risk of severe congestive heart failure in cancer patients: an up-to-date meta-analysis with a focus on different subgroups","volume":"34","author":"Qi","year":"2014","journal-title":"Clin. Drug Invest."},{"key":"10.1016\/j.biopha.2023.115373_bib48","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","article-title":"Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management","volume":"19","author":"Cooper","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2023.115373_bib49","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jaccao.2019.10.006","article-title":"Osimertinib-induced cardiotoxicity: a retrospective review of the FDA adverse events reporting system (FAERS)","volume":"1","author":"Anand","year":"2019","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.biopha.2023.115373_bib50","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jare.2020.09.006","article-title":"PD-1\/PDL-1 inhibitors and cardiotoxicity; molecular, etiological and management outlines","volume":"29","author":"Safi","year":"2021","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.biopha.2023.115373_bib51","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/nm955","article-title":"Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice","volume":"9","author":"Okazaki","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.biopha.2023.115373_bib52","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.biopha.2023.115373_bib53","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1517\/14656566.6.7.1073","article-title":"The role of taxanes in the treatment of breast cancer","volume":"6","author":"Nabholtz","year":"2005","journal-title":"Expert Opin. Pharm."},{"key":"10.1016\/j.biopha.2023.115373_bib54","first-page":"117","article-title":"A reassessment of cardiac toxicity associated with Taxol","author":"Arbuck","year":"1993","journal-title":"J. Natl. Cancer Inst. Monogr."},{"issue":"Suppl 3","key":"10.1016\/j.biopha.2023.115373_bib55","first-page":"154","article-title":"[Cardiotoxicity of 5-fluorouracil]","volume":"91","author":"Teixeira","year":"2004","journal-title":"Bull. Cancer"},{"key":"10.1016\/j.biopha.2023.115373_bib56","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/cam4.3568","article-title":"Real-world experience of carfilzomib-associated cardiovascular adverse events: SEER-Medicare data set analysis","volume":"10","author":"Bishnoi","year":"2021","journal-title":"Cancer Med"},{"key":"10.1016\/j.biopha.2023.115373_bib57","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1126\/science.6093249","article-title":"Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II","volume":"226","author":"Tewey","year":"1984","journal-title":"Science"},{"key":"10.1016\/j.biopha.2023.115373_bib58","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1042\/CS20200301","article-title":"Molecular mechanisms of anthracycline cardiovascular toxicity","volume":"135","author":"Narezkina","year":"2021","journal-title":"Clin. Sci. (Lond. )"},{"key":"10.1016\/j.biopha.2023.115373_bib59","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/nm.2919","article-title":"Identification of the molecular basis of doxorubicin-induced cardiotoxicity","volume":"18","author":"Zhang","year":"2012","journal-title":"Nat. Med"},{"key":"10.1016\/j.biopha.2023.115373_bib60","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/BF00263895","article-title":"Similar changes in cardiac morphology and DNA synthesis induced by doxorubicin and 4'-epi-doxorubicin","volume":"15","author":"Wassermann","year":"1985","journal-title":"Cancer Chemother. Pharm."},{"key":"10.1016\/j.biopha.2023.115373_bib61","doi-asserted-by":"crossref","first-page":"19672","DOI":"10.1074\/jbc.RA118.004673","article-title":"Inhibition of cyclin-dependent kinase 2 protects against doxorubicin-induced cardiomyocyte apoptosis and cardiomyopathy","volume":"293","author":"Xia","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2023.115373_bib62","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/0022-2828(81)90242-X","article-title":"Heart mitochondrial DNA synthesis: preferential inhibition by adriamycin","volume":"13","author":"Hixon","year":"1981","journal-title":"J. Mol. Cell Cardiol."},{"key":"10.1016\/j.biopha.2023.115373_bib63","first-page":"327","article-title":"Anthracycline cardiotoxicity: in vivo and in vitro effects on biochemical parameters and heart ultrastructure of the rat","volume":"48","author":"Cini Neri","year":"1991","journal-title":"Oncology"},{"key":"10.1016\/j.biopha.2023.115373_bib64","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0009-2797(81)90120-4","article-title":"Comparative inhibition of nuclear RNA synthesis in cultured mouse leukemia L1210 cells by adriamycin and 4'-epi-adriamycin","volume":"37","author":"Wilson","year":"1981","journal-title":"Chem. Biol. Inter."},{"key":"10.1016\/j.biopha.2023.115373_bib65","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/bies.20160","article-title":"The anthracycline antibiotics: antitumor drugs that alter chromatin structure","volume":"27","author":"Rabbani","year":"2005","journal-title":"Bioessays"},{"key":"10.1016\/j.biopha.2023.115373_bib66","doi-asserted-by":"crossref","first-page":"7429","DOI":"10.1021\/ja101495v","article-title":"Transcription inhibition by platinum-DNA cross-links in live mammalian cells","volume":"132","author":"Ang","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.biopha.2023.115373_bib67","article-title":"Cisplatin-induced bradycardia: a silent risk observed in two different clinical cases","volume":"13","author":"Bin Naeem","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.biopha.2023.115373_bib68","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1089\/rej.2010.1141","article-title":"Platinum-based compounds and risk for cardiovascular toxicity in the elderly: role of the antioxidants in chemoprevention","volume":"14","author":"Ferroni","year":"2011","journal-title":"Rejuvenation Res."},{"key":"10.1016\/j.biopha.2023.115373_bib69","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1159\/000526256","article-title":"Trabectedin cardiotoxicity in soft tissue sarcoma: a case series and clinical insights","volume":"15","author":"Gent","year":"2022","journal-title":"Case Rep. Oncol."},{"key":"10.1016\/j.biopha.2023.115373_bib70","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1177\/1078155220982044","article-title":"Gemcitabine-induced dilated-cardiomyopathy in patient with platinum-refractory ovarian-cancer: A case report and literature review","volume":"27","author":"Raimondi","year":"2021","journal-title":"J. Oncol. Pharm. Pr."},{"key":"10.1016\/j.biopha.2023.115373_bib71","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2217\/nnm-2020-0199","article-title":"Nano liposomal and cubosomal formulations with platinum-based anticancer agents: therapeutic advances and challenges","volume":"15","author":"Alavi","year":"2020","journal-title":"Nanomed. (Lond. )"},{"key":"10.1016\/j.biopha.2023.115373_bib72","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.bpj.2016.02.030","article-title":"Platinum-Based Drugs and DNA Interactions Studied by Single-Molecule and Bulk Measurements","volume":"110","author":"Salerno","year":"2016","journal-title":"Biophys. J."},{"key":"10.1016\/j.biopha.2023.115373_bib73","first-page":"2435","article-title":"ERK1\/2\/p53 and NF-\u03baB dependent-PUMA activation involves in doxorubicin-induced cardiomyocyte apoptosis","volume":"20","author":"Zhang","year":"2016","journal-title":"Eur. Rev. Med Pharm. Sci."},{"key":"10.1016\/j.biopha.2023.115373_bib74","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.886","article-title":"Jadomycins: a potential chemotherapy for multii-drug resistant metastatic breast cancer","volume":"9","author":"Bonitto","year":"2021","journal-title":"Pharm. Res Perspect."},{"key":"10.1016\/j.biopha.2023.115373_bib75","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1042\/CS20210311","article-title":"Prodrug of ICRF-193 provides promising protective effects against chronic anthracycline cardiotoxicity in a rabbit model in vivo","volume":"135","author":"Koll\u00e1rov\u00e1-Br\u00e1zdov\u00e1","year":"2021","journal-title":"Clin. Sci. (Lond. )"},{"key":"10.1016\/j.biopha.2023.115373_bib76","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/oxfordjournals.annonc.a058584","article-title":"DNA topoisomerase I and II as targets for rational design of new anticancer drugs","volume":"4","author":"Cummings","year":"1993","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2023.115373_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2022.111816","article-title":"Pyridoxal hydrochloride thiosemicarbazones with copper ions inhibit cell division via Topo-I and Topo-II\u0251","volume":"232","author":"Qi","year":"2022","journal-title":"J. Inorg. Biochem"},{"key":"10.1016\/j.biopha.2023.115373_bib78","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1039\/D1DT03700E","article-title":"Platinum complexes as inhibitors of DNA repair protein Ku70 and topoisomerase II\u03b1 in cancer cells","volume":"51","author":"Zhang","year":"2022","journal-title":"Dalton Trans."},{"key":"10.1016\/j.biopha.2023.115373_bib79","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/dna.2008.0727","article-title":"Transfer RNA bindings to antitumor estradiol-platinum(II) hybrid and cisplatin","volume":"27","author":"N'Soukpo\u00e9-Kossi","year":"2008","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.biopha.2023.115373_bib80","first-page":"23","article-title":"A review of the recent developments of molecular hybrids targeting tubulin polymerization","author":"Ebenezer","year":"2022","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2023.115373_bib81","doi-asserted-by":"crossref","first-page":"17001","DOI":"10.1074\/jbc.C116.737346","article-title":"Fatostatin inhibits cancer cell proliferation by affecting mitotic microtubule spindle assembly and cell division","volume":"291","author":"Gholkar","year":"2016","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2023.115373_bib82","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1007\/s11010-020-03985-3","article-title":"RIP1\/RIP3\/MLKL-mediated necroptosis contributes to vinblastine-induced myocardial damage","volume":"476","author":"Zhou","year":"2021","journal-title":"Mol. Cell Biochem"},{"key":"10.1016\/j.biopha.2023.115373_bib83","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1007\/s12015-022-10370-8","article-title":"Telomeres and mitochondrial metabolism: implications for cellular senescence and age-related diseases","volume":"18","author":"Gao","year":"2022","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.biopha.2023.115373_bib84","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1161\/01.CIR.100.20.2100","article-title":"MAPK superfamily plays an important role in daunomycin-induced apoptosis of cardiac myocytes","volume":"100","author":"Zhu","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2023.115373_bib85","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/951539","article-title":"Mitochondria death\/survival signaling pathways in cardiotoxicity induced by anthracyclines and anticancer-targeted therapies","volume":"2012","author":"Montaigne","year":"2012","journal-title":"Biochem Res Int"},{"key":"10.1016\/j.biopha.2023.115373_bib86","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1159\/000479407","article-title":"Cyclin-Dependent Kinase Inhibitor p21WAF1\/CIP1 Facilitates the Development of Cardiac Hypertrophy","volume":"42","author":"Tong","year":"2017","journal-title":"Cell Physiol. Biochem"},{"key":"10.1016\/j.biopha.2023.115373_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yjmcc.2017.01.007","article-title":"Autophagic dysregulation in doxorubicin cardiomyopathy","volume":"104","author":"Bartlett","year":"2017","journal-title":"J. Mol. Cell Cardiol."},{"key":"10.1016\/j.biopha.2023.115373_bib88","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.apsb.2018.10.008","article-title":"Chrysophanol protects against doxorubicin-induced cardiotoxicity by suppressing cellular PARylation","volume":"9","author":"Lu","year":"2019","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.biopha.2023.115373_bib89","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1172\/JCI72931","article-title":"Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation","volume":"124","author":"Ichikawa","year":"2014","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.biopha.2023.115373_bib90","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.ejca.2005.03.027","article-title":"The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC)","volume":"41","author":"Ng","year":"2005","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.biopha.2023.115373_bib91","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/s41419-021-03614-x","article-title":"Regulated cell death pathways in doxorubicin-induced cardiotoxicity","volume":"12","author":"Christidi","year":"2021","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2023.115373_bib92","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0021-5198(19)52945-6","article-title":"Cardiotoxic effects of 5-fluorouracil in the guinea pig","volume":"30","author":"Matsubara","year":"1980","journal-title":"Jpn J. Pharm."},{"key":"10.1016\/j.biopha.2023.115373_bib93","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8949450","article-title":"Ex vivo cardiotoxicity of antineoplastic casiopeinas is mediated through energetic dysfunction and triggered mitochondrial-dependent apoptosis","volume":"2018","author":"Silva-Platas","year":"2018","journal-title":"Oxid. Med Cell Longev."},{"key":"10.1016\/j.biopha.2023.115373_bib94","doi-asserted-by":"crossref","first-page":"eabn8017","DOI":"10.1126\/scisignal.abn8017","article-title":"Doxorubicin causes ferroptosis and cardiotoxicity by intercalating into mitochondrial DNA and disrupting Alas1-dependent heme synthesis","volume":"15","author":"Abe","year":"2022","journal-title":"Sci. Signal"},{"key":"10.1016\/j.biopha.2023.115373_bib95","article-title":"The role of mitochondrial quality control in anthracycline-induced cardiotoxicity: from bench to bedside","volume":"2022","author":"Li","year":"2022","journal-title":"Oxid. Med Cell Longev."},{"key":"10.1016\/j.biopha.2023.115373_bib96","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/CMAR.S77400","article-title":"Cancer therapy and cardiovascular risk: focus on bevacizumab","volume":"7","author":"Economopoulou","year":"2015","journal-title":"Cancer Manag Res"},{"key":"10.1016\/j.biopha.2023.115373_bib97","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkel\u00e4","year":"2006","journal-title":"Nat. Med"},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2023.115373_bib98","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.thromres.2021.12.017","article-title":"Cardiovascular toxic effects of antitumor agents: pathogenetic mechanisms","volume":"213","author":"Pantazi","year":"2022","journal-title":"Thromb. Res"},{"key":"10.1016\/j.biopha.2023.115373_bib99","first-page":"249","article-title":"[Cardiotoxicity induced by 5-fluorouracil","volume":"184","author":"Bl\u00e1zquez Encinar","year":"1989","journal-title":"Rev. Lit. ]. Rev. Clin. Esp."},{"key":"10.1016\/j.biopha.2023.115373_bib100","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s11912-020-00931-w","article-title":"Proteasome inhibitor-related cardiotoxicity: mechanisms, diagnosis, and management","volume":"22","author":"Wu","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.biopha.2023.115373_bib101","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s10495-008-0214-9","article-title":"Pravastatin attenuates carboplatin-induced cardiotoxicity via inhibition of oxidative stress associated apoptosis","volume":"13","author":"Cheng","year":"2008","journal-title":"Apoptosis"},{"key":"10.1016\/j.biopha.2023.115373_bib102","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/j.1440-1681.2009.05323.x","article-title":"Cisplatin compromises myocardial contractile function and mitochondrial ultrastructure: role of endoplasmic reticulum stress","volume":"37","author":"Ma","year":"2010","journal-title":"Clin. Exp. Pharm. Physiol."},{"key":"10.1016\/j.biopha.2023.115373_bib103","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/j.bcp.2012.01.016","article-title":"Vinca alkaloids cause aberrant ROS-mediated JNK activation, Mcl-1 downregulation, DNA damage, mitochondrial dysfunction, and apoptosis in lung adenocarcinoma cells","volume":"83","author":"Chiu","year":"2012","journal-title":"Biochem Pharm."},{"key":"10.1016\/j.biopha.2023.115373_bib104","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1016\/j.jtho.2021.07.030","article-title":"Pharmacovigilance analysis of cardiac toxicities associated with targeted therapies for metastatic NSCLC","volume":"16","author":"Waliany","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.biopha.2023.115373_bib105","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12968-016-0308-4","article-title":"Cardiac T1 mapping and extracellular volume (ECV) in clinical practice: a comprehensive review","volume":"18","author":"Haaf","year":"2016","journal-title":"J. Cardiovasc Magn. Reson"},{"key":"10.1016\/j.biopha.2023.115373_bib106","doi-asserted-by":"crossref","first-page":"E64","DOI":"10.1093\/eurheartj\/suw022","article-title":"Novel cardiac magnetic resonance biomarkers: native T1 and extracellular volume myocardial mapping","volume":"18","author":"Canna\u00f2","year":"2016","journal-title":"Eur. Heart J. Suppl."},{"key":"10.1016\/j.biopha.2023.115373_bib107","first-page":"4","article-title":"Myocardial fibrosis quantified by extracellular volume is associated with subsequent hospitalization for heart failure, death, or both across the spectrum of ejection fraction and heart failure stage","author":"Schelbert","year":"2015","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.biopha.2023.115373_bib108","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13244-022-01224-5","article-title":"Myocardial extracellular volume derived from contrast-enhanced chest computed tomography for longitudinal evaluation of cardiotoxicity in patients with breast cancer treated with anthracyclines","volume":"13","author":"Tu","year":"2022","journal-title":"Insights Imaging"},{"key":"10.1016\/j.biopha.2023.115373_bib109","doi-asserted-by":"crossref","first-page":"934","DOI":"10.21037\/qims.2020.04.05","article-title":"Assessment of myocardial extracellular volume on body computed tomography in breast cancer patients treated with anthracyclines","volume":"10","author":"Monti","year":"2020","journal-title":"Quant. Imaging Med Surg."},{"key":"10.1016\/j.biopha.2023.115373_bib110","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1007\/s00204-022-03280-8","article-title":"microRNAs signatures as potential biomarkers of structural cardiotoxicity in human-induced pluripotent stem-cell derived cardiomyocytes","volume":"96","author":"Gryshkova","year":"2022","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.biopha.2023.115373_bib111","doi-asserted-by":"crossref","first-page":"11629","DOI":"10.1021\/acs.analchem.8b03207","article-title":"Mitochondrial peroxynitrite mediation of anthracycline-induced cardiotoxicity as visualized by a two-photon near-infrared fluorescent probe","volume":"90","author":"Xie","year":"2018","journal-title":"Anal. Chem."},{"key":"10.1016\/j.biopha.2023.115373_bib112","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1186\/s12885-021-09050-6","article-title":"Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study","volume":"21","author":"Zhang","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2023.115373_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112307","article-title":"Preclinical toxicological study of long-circulating and fusogenic liposomes co-encapsulating paclitaxel and doxorubicin in synergic ratio","volume":"144","author":"Roque","year":"2021","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2023.115373_bib114","doi-asserted-by":"crossref","first-page":"11425","DOI":"10.1038\/s41598-020-68205-w","article-title":"Co-administration of H-ferritin-doxorubicin and Trastuzumab in neoadjuvant setting improves efficacy and prevents cardiotoxicity in HER2\u2009+\u2009murine breast cancer model","volume":"10","author":"Andreata","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2023.115373_bib115","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920985632","article-title":"Phase II study of liposomal doxorubicin, docetaxel and trastuzumab in combination with metformin as neoadjuvant therapy for HER2-positive breast cancer","volume":"13","author":"Rocca","year":"2021","journal-title":"Ther. Adv. Med Oncol."},{"key":"10.1016\/j.biopha.2023.115373_bib116","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.biopha.2023.115373_bib117","article-title":"AHA\/ACC\/HFSA guideline for the management of heart failure","volume":"28","author":"Writing Committee","year":"2022","journal-title":"J. Card. Fail"},{"key":"10.1016\/j.biopha.2023.115373_bib118","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.hfc.2022.02.002","article-title":"Clinical practice guidelines in cardio-oncology","volume":"18","author":"Leong","year":"2022","journal-title":"Heart Fail Clin."},{"key":"10.1016\/j.biopha.2023.115373_bib119","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.2008.17.2627","article-title":"American society of clinical oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants","volume":"27","author":"Hensley","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.biopha.2023.115373_bib120","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1038\/s41598-021-83688-x","article-title":"Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase II\u03b2 inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity","volume":"11","author":"Bavlovi\u010d Pisk\u00e1\u010dkov\u00e1","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2023.115373_bib121","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tox.2017.09.012","article-title":"Investigation of novel dexrazoxane analogue JR-311 shows significant cardioprotective effects through topoisomerase IIbeta but not its iron chelating metabolite","volume":"392","author":"Bures","year":"2017","journal-title":"Toxicology"},{"key":"10.1016\/j.biopha.2023.115373_bib122","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.biopha.2017.08.118","article-title":"Effects of Ganoderma lucidum polysaccharides against doxorubicin-induced cardiotoxicity","volume":"95","author":"Xu","year":"2017","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2023.115373_bib123","doi-asserted-by":"crossref","first-page":"65802","DOI":"10.1007\/s11356-021-15409-w","article-title":"Antioxidant, anti-inflammatory, and anti-apoptotic effects of crocin against doxorubicin-induced myocardial toxicity in rats","volume":"28","author":"Abdulkareem Aljumaily","year":"2021","journal-title":"Environ. Sci. Pollut. Res. Int."},{"key":"10.1016\/j.biopha.2023.115373_bib124","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1080\/01635581.2021.1931362","article-title":"In vivo and in vitro protective effects of rosmarinic acid against doxorubicin-induced cardiotoxicity","volume":"74","author":"Rahbardar","year":"2022","journal-title":"Nutr. Cancer"},{"key":"10.1016\/j.biopha.2023.115373_bib125","article-title":"Exercise cardio-oncology: exercise as a potential therapeutic modality in the management of anthracycline-induced cardiotoxicity","volume":"8","author":"Kang","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.biopha.2023.115373_bib126","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1161\/CIRCULATIONAHA.109.895771","article-title":"Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function","volume":"121","author":"De Angelis","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.biopha.2023.115373_bib127","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jaccao.2020.09.001","article-title":"Allogeneic mesenchymal cell therapy in anthracycline-induced cardiomyopathy heart failure patients: the CCTRN SENECA trial","volume":"2","author":"Bolli","year":"2020","journal-title":"JACC CardioOncol"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223011691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223011691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T07:08:32Z","timestamp":1782371312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223011691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":127,"alternative-id":["S0753332223011691"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115373","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.115373","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"115373"}}